KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Buildings (2016 - 2017)

Regeneron Pharmaceuticals has reported Buildings over the past 6 years, most recently at $1.4 billion for Q4 2017.

  • Quarterly results put Buildings at $1.4 billion for Q4 2017, up 12.77% from a year ago — trailing twelve months through Dec 2017 was $1.4 billion (up 12.77% YoY), and the annual figure for FY2017 was $1.4 billion, up 12.77%.
  • Buildings for Q4 2017 was $1.4 billion at Regeneron Pharmaceuticals, up from $1.3 billion in the prior quarter.
  • Over the last five years, Buildings for REGN hit a ceiling of $1.4 billion in Q4 2017 and a floor of $343.4 million in Q4 2013.
  • Median Buildings over the past 5 years was $760.5 million (2015), compared with a mean of $844.5 million.
  • Biggest five-year swings in Buildings: skyrocketed 90.61% in 2015 and later grew 12.77% in 2017.
  • Regeneron Pharmaceuticals' Buildings stood at $343.4 million in 2013, then increased by 16.2% to $399.0 million in 2014, then skyrocketed by 90.61% to $760.5 million in 2015, then surged by 68.08% to $1.3 billion in 2016, then grew by 12.77% to $1.4 billion in 2017.
  • The last three reported values for Buildings were $1.4 billion (Q4 2017), $1.3 billion (Q4 2016), and $760.5 million (Q4 2015) per Business Quant data.